Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Ruane

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
AIDS Research and Human Retroviruses|November 19, 2010
A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s)Peter Ruane, Brian Alas, Robert Ryan, et al.
The Lancet. HIV|October 16, 2018
Antiretroviral switch studies do matterEric S Daar, Peter Ruane, Edwin DeJesus, et al.
Plos One|January 5, 2012
EB1 is required for spindle symmetry in mammalian mitosisAnke Brüning-Richardson, Kelly J Langford, Peter Ruane, et al.
The Journal of Antimicrobial Chemotherapy|February 11, 2014
Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adultsMartin Markowitz, Andrew Zolopa, Kathleen Squires, et al.
HIV Clinical Trials|August 30, 2008
Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once dailyRichard Elion, Calvin Cohen, Douglas Ward, et al.
The Journal of Cell Biology|November 26, 2014
Dynein light intermediate chains maintain spindle bipolarity by functioning in centriole cohesionLaura A Jones, Cécile Villemant, Toby Starborg, et al.
The New England Journal of Medicine|June 28, 2002
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infectionSharon Walmsley, Barry Bernstein, Martin King, et al.
HIV Clinical Trials|May 14, 2008
Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabineEdwin DeJesus, Peter Ruane, Cheryl McDonald, et al.
Antimicrobial Agents and Chemotherapy|July 28, 2010
HIV-1 protease mutations and protease inhibitor cross-resistanceSoo-Yon Rhee, Jonathan Taylor, W Jeffrey Fessel, et al.
AIDS (London, England)|June 5, 2002
Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind studyRobert T Schooley, Peter Ruane, Robert A Myers, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
AIDS Research and Human Retroviruses|November 19, 2010
A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s)Peter Ruane, Brian Alas, Robert Ryan, et al.
The Lancet. HIV|October 16, 2018
Antiretroviral switch studies do matterEric S Daar, Peter Ruane, Edwin DeJesus, et al.
Plos One|January 5, 2012
EB1 is required for spindle symmetry in mammalian mitosisAnke Brüning-Richardson, Kelly J Langford, Peter Ruane, et al.
The Journal of Antimicrobial Chemotherapy|February 11, 2014
Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adultsMartin Markowitz, Andrew Zolopa, Kathleen Squires, et al.
HIV Clinical Trials|August 30, 2008
Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once dailyRichard Elion, Calvin Cohen, Douglas Ward, et al.
The Journal of Cell Biology|November 26, 2014
Dynein light intermediate chains maintain spindle bipolarity by functioning in centriole cohesionLaura A Jones, Cécile Villemant, Toby Starborg, et al.
The New England Journal of Medicine|June 28, 2002
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infectionSharon Walmsley, Barry Bernstein, Martin King, et al.
HIV Clinical Trials|May 14, 2008
Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabineEdwin DeJesus, Peter Ruane, Cheryl McDonald, et al.
Antimicrobial Agents and Chemotherapy|July 28, 2010
HIV-1 protease mutations and protease inhibitor cross-resistanceSoo-Yon Rhee, Jonathan Taylor, W Jeffrey Fessel, et al.
AIDS (London, England)|June 5, 2002
Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind studyRobert T Schooley, Peter Ruane, Robert A Myers, et al.
Pageof 4